Literature DB >> 4085151

Lymphoid irradiation in intractable rheumatoid arthritis: effects on the production of immunoglobulins and rheumatoid factors.

J G Hanly, J Hassan, M Moriarty, A Whelan, C Feighery, B Bresnihan.   

Abstract

Changes in the production of immunoglobulins and rheumatoid factors (RF's) were studied in 20 patients with intractable rheumatoid arthritis (RA) following total doses of 750 rad or 2,000 rad lymphoid irradiation. Over a 12 month follow up period there was no consistent change in absolute serum or synovial fluid levels, or in synovial membrane production of either total IgG, IgA or IgM, or the corresponding RF fractions. The invitro production of immunoglobulins and IgM RF by peripheral blood mononuclear cells was also unaltered, except for one patient who had a dramatic rise in IgM RF production. Over the same period there was a significant overall reduction in disease activity following both doses of radiotherapy. It is concluded that the clinical response which occurs following lymphoid irradiation is not due to a reduction in RF production. Furthermore, the production of RF's appears to be unaffected by the changes in T cell immunity which occur following lymphoid irradiation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4085151      PMCID: PMC1577473     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation.

Authors:  I Kushner; J A Somerville
Journal:  Arthritis Rheum       Date:  1971 Sep-Oct

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Use of laser nephelometry in the measurement of serum proteins.

Authors:  C D Deaton; K W Maxwell; R S Smith; R L Creveling
Journal:  Clin Chem       Date:  1976-09       Impact factor: 8.327

5.  Treatment of intractable rheumatoid arthritis with total lymphoid irradiation.

Authors:  B L Kotzin; S Strober; E G Engleman; A Calin; R T Hoppe; G S Kansas; C P Terrell; H S Kaplan
Journal:  N Engl J Med       Date:  1981-10-22       Impact factor: 91.245

6.  Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis.

Authors:  D E Trentham; J A Belli; R J Anderson; J A Buckley; E J Goetzl; J R David; K F Austen
Journal:  N Engl J Med       Date:  1981-10-22       Impact factor: 91.245

7.  Radioimmunoassay of IgG and IgM rheumatoid factors reacting with human IgG.

Authors:  D A Carson; S Lawrance; M A Catalano; J H Vaughan; G Abraham
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

8.  The influence of chrysotherapy on serum protein and immunoglobulin levels, rheumatoid factor, and antiepithelial antibody titers.

Authors:  N L Gottlieb; I M Kiem; N S Penneys; D R Schultz
Journal:  J Lab Clin Med       Date:  1975-12

9.  The molecular basis of self-association of antibodies to IgG (rheumatoid factors) in rheumatoid arthritis.

Authors:  R M Pope; D C Teller; M Mannik
Journal:  Proc Natl Acad Sci U S A       Date:  1974-02       Impact factor: 11.205

10.  IgG rheumatoid factor. Relationship to seropositive rheumatoid arthritis and absence in seronegative disorders.

Authors:  R M Pope; S J McDuffy
Journal:  Arthritis Rheum       Date:  1979-09
View more
  2 in total

1.  Lymphocyte infiltration and the synthesis of IgM and IgA rheumatoid factors by rheumatoid synovial membrane.

Authors:  M Soden; A Whelan; C Feighery; B Bresnihan
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  IL-2 enhances polyclonal IgM but not IgM-rheumatoid factor synthesis by activated human peripheral blood B cells.

Authors:  M Callaghan; A Whelan; C Feighery; B Bresnihan
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.